#NACFC2021 – Trikafta May Benefit Some Lung Transplant Recipients

#NACFC2021 – Trikafta May Benefit Some Lung Transplant Recipients

311582

#NACFC2021 – Trikafta May Benefit Some Lung Transplant Recipients

Treatment with Trikafta may improve nutritional status or lessen anemia among some people with cystic fibrosis (CF) who have received a lung transplant, but more research is needed to understand the potential benefits — and risks — of using the triple-combination medication in this particular patient population. That’s according to data discussed at the 2021 North American Cystic Fibrosis Conference (NACFC), held virtually Nov. 2–5, in an oral presentation titled “Use of elexacaftor/tezacaftor/ivacaftor among CF…

You must be logged in to read/download the full post.